Mesoblast Seeks New Partner In Chronic Heart Failure, To Replace Teva
Executive Summary
The surprise parting of ways between Mesoblast Ltd. and Teva Pharmaceutical Industries Ltd. leaves the Australian group seeking a new partner to pursue ongoing Phase III trials and subsequent commercialization for chronic heart failure product MPC-150-IM.